Royal Bank of Canada
LYEL icon

Royal Bank of Canada’s Lyell Immunopharma LYEL Stock Holding History

Royal Bank of Canada’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6K Buy
251
+227
+946% +$5.31K ﹤0.01% 6372
2025
Q4 		$1K Sell
24
-4,163
-99% -$93.2K ﹤0.01% 7013
2025
Q3 		$68K Buy
4,187
+4,162
+16,648% +$47.5K ﹤0.01% 5693
2025
Q2 		$0 Sell
25
-962
-97% -$8.77K ﹤0.01% 7205
2025
Q1 		$11K Sell
987
-190
-16% -$2.33K ﹤0.01% 6126
2024
Q4 		$15K Buy
1,177
+342
+41% +$6.78K ﹤0.01% 6230
2024
Q3 		$23K Buy
835
+79
+10% +$2.32K ﹤0.01% 6050
2024
Q2 		$22K Buy
756
+555
+276% +$26.4K ﹤0.01% 6035
2024
Q1 		$9K Sell
201
-2,354
-92% -$101K ﹤0.01% 6240
2023
Q4 		$99K Buy
2,555
+1,096
+75% +$39.5K ﹤0.01% 5629
2023
Q3 		$43K Buy
1,459
+554
+61% +$26.3K ﹤0.01% 5859
2023
Q2 		$58K Buy
905
+421
+87% +$23.3K ﹤0.01% 5700
2023
Q1 		$23K Sell
484
-592
-55% -$31.7K ﹤0.01% 5972
2022
Q4 		$74K Buy
1,076
+971
+925% +$96.5K ﹤0.01% 5659
2022
Q3 		$15K Buy
105
+56
+114% +$7.58K ﹤0.01% 6259
2022
Q2 		$6K Sell
49
-407
-89% -$41.6K ﹤0.01% 6584
2022
Q1 		$46K Buy
456
+197
+76% +$23.9K ﹤0.01% 6154
2021
Q4 		$40K Buy
259
+118
+84% +$26.3K ﹤0.01% 6498
2021
Q3 		$41K Buy
+141
New +$42.2K ﹤0.01% 6278

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada's LYEL Position: Q1 2026 in Review

Royal Bank of Canada increased its Lyell Immunopharma (LYEL) stake by 946% in Q1 2026, buying an estimated $5.31K and bringing the position to 251 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #6372.

Royal Bank of Canada first reported a position in LYEL in Q3 2021 and has held it in 19 quarters since. The position peaked at $99K in Q4 2023. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Royal Bank of Canada held 251 shares of Lyell Immunopharma worth $6K as of Q1 2026.
  • Royal Bank of Canada bought 227 Lyell Immunopharma shares in Q1 2026, an estimated $5.31K.
  • Lyell Immunopharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6372 holding.
  • Royal Bank of Canada first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 19 quarters since.
  • Royal Bank of Canada's Lyell Immunopharma position peaked at $99K in Q4 2023.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.